Does OBINUTUZUMAB Cause Interstitial lung disease? 108 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 108 reports of Interstitial lung disease have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.8% of all adverse event reports for OBINUTUZUMAB.
108
Reports of Interstitial lung disease with OBINUTUZUMAB
0.8%
of all OBINUTUZUMAB reports
16
Deaths
63
Hospitalizations
How Dangerous Is Interstitial lung disease From OBINUTUZUMAB?
Of the 108 reports, 16 (14.8%) resulted in death, 63 (58.3%) required hospitalization, and 2 (1.9%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 108 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which OBINUTUZUMAB Alternatives Have Lower Interstitial lung disease Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE